An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome - Galbusera, Miriam; Noris, Marina; Gastoldi, Sara; Bresin, Elena; Mele, Caterina; Breno, Matteo; Cuccarolo, Paola; Alberti, Marta; Valoti, Elisabetta; Piras, Rossella; Donadelli, Roberta; Vivarelli, Marina; et al. (American journal of kidney diseases, 2019)
Keywords: Adult; anti-C5 monoclonal antibody; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacokinetics; Atypical hemolytic uremic syndrome (aHUS); Atypical Hemolytic Uremic Syndrome - blood; Atypical Hemolytic Uremic Syndrome - drug therapy; C5b-9 deposition; case series; Complement Activation - drug effects; complement alternative pathway; Complement Factor H - analysis; Complement Factor H - genetics; Complement Inactivating Agents - administration & dosage; Complement Inactivating Agents - pharmacokinetics; Complement Membrane Attack Complex - analysis; Dose-Response Relationship, Drug; Drug Monitoring - methods; eculizumab; eculizumab discontinuation; eculizumab tapering; endothelial cells; Endothelium, Vascular - metabolism; ex vivo test; Female; Humans; In Vitro Techniques - methods; Male; predictive biomarker; primary aHUS; prognosis; relapse; remission; Reproducibility of Results; secondary aHUS; Secondary Prevention - methods; Secondary Prevention - statistics & numerical data; terminal complement pathway; ex vivo test; endothelial cells; anti-C5 monoclonal antibody; relapse; terminal complement pathway; case series; eculizumab discontinuation; Atypical hemolytic uremic syndrome (aHUS); eculizumab; secondary aHUS; prognosis; eculizumab tapering; primary aHUS; remission; predictive biomarker; complement alternative pathway; C5b-9 deposition